Alpha-1 Antitrypsin Deficiency Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceutica

Alpha-1 Antitrypsin Deficiency Pipeline constitutes 12+ key companies continuously working towards developing 12+ Alpha-1 Antitrypsin Deficiency treatment therapies, analyzes DelveInsight.

Alpha-1 Antitrypsin Deficiency Overview:

Alpha-1-antitrypsin (AAT) is a liver-produced protein that protects tissues from damage caused by immune system agents. In AAT deficiency, the body produces insufficient AAT, leading to lung tissue damage. This condition is inherited, with its severity depending on the specific gene abnormalities passed from each parent. In the U.S., an estimated 80,000 to 100,000 people are affected by AAT deficiency.

AAT deficiency occurs when one or both parents pass on an abnormal gene regulating AAT production. The severity of the condition varies based on the type of gene inherited, with both abnormal genes leading to more severe disease. While not everyone with AAT deficiency develops emphysema (a form of COPD), individuals are at higher risk of early lung disease if they smoke, are exposed to secondhand smoke, work in dusty environments, have a family history of emphysema, or have asthma or repeated lung infections.

Request for a detailed insights report on Alpha-1 Antitrypsin Deficiency pipeline insights @ https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Alpha-1 Antitrypsin Deficiency Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alpha-1 Antitrypsin Deficiency Therapeutics Market.

Key Takeaways from the Alpha-1 Antitrypsin Deficiency Pipeline Report

DelveInsight's Alpha-1 Antitrypsin Deficiency pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Alpha-1 Antitrypsin Deficiency treatment.
In June 2024, Beam Therapeutics announced the first patient in Phase 1/2 Trial of BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD).
Key Alpha-1 Antitrypsin Deficiency companies such as Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada, Ltd, and others are evaluating new drugs for Alpha-1 Antitrypsin Deficiency to improve the treatment landscape.
Promising Alpha-1 Antitrypsin Deficiency pipeline therapies in various stages of development include ARO AAT, ALN-AAT02, and others.

Alpha-1 Antitrypsin Deficiency Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Alpha-1 Antitrypsin Deficiency Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha-1 Antitrypsin Deficiency treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alpha-1 Antitrypsin Deficiency market.

Download our free sample page report on Alpha-1 Antitrypsin Deficiency pipeline insights @ https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Alpha-1 Antitrypsin Deficiency Emerging Drugs

ARO AAT: Arrowhead Pharmaceuticals
ALN-AAT02: Alnylam Pharmaceuticals

Alpha-1 Antitrypsin Deficiency Companies

There are over 12 major companies working on therapies for Alpha-1 Antitrypsin Deficiency. Among them, Deerland Probiotics & Enzymes has drug candidates for the condition in the most advanced stage, specifically Phase III.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Alpha-1 Antitrypsin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Alpha-1 Antitrypsin Deficiency Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Alpha-1 Antitrypsin Deficiency Therapies and Key Companies: Alpha-1 Antitrypsin Deficiency Clinical Trials and advancements @ https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Alpha-1 Antitrypsin Deficiency Pipeline Therapeutic Assessment
• Alpha-1 Antitrypsin Deficiency Assessment by Product Type
• Alpha-1 Antitrypsin Deficiency By Stage
• Alpha-1 Antitrypsin Deficiency Assessment by Route of Administration
• Alpha-1 Antitrypsin Deficiency Assessment by Molecule Type

Download Alpha-1 Antitrypsin Deficiency Sample report to know in detail about the Alpha-1 Antitrypsin Deficiency treatment market @ Alpha-1 Antitrypsin Deficiency Therapeutic Assessment @ https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Alpha-1 Antitrypsin Deficiency Current Treatment Patterns
4. Alpha-1 Antitrypsin Deficiency - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Alpha-1 Antitrypsin Deficiency Late-Stage Products (Phase-III)
7. Alpha-1 Antitrypsin Deficiency Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alpha-1 Antitrypsin Deficiency Discontinued Products
13. Alpha-1 Antitrypsin Deficiency Product Profiles
14. Alpha-1 Antitrypsin Deficiency Key Companies
15. Alpha-1 Antitrypsin Deficiency Key Products
16. Dormant and Discontinued Products
17. Alpha-1 Antitrypsin Deficiency Unmet Needs
18. Alpha-1 Antitrypsin Deficiency Future Perspectives
19. Alpha-1 Antitrypsin Deficiency Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Alpha-1 Antitrypsin Deficiency Pipeline Reports Offerings: https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.